Navigation Links
Study aims to induce recovery from ankylosing spondylitis
Date:7/21/2009

Chinese patients will soon have the opportunity to take part in a study of a novel therapy aimed at reversing the autoimmune disease, ankylosing spondylitis. Approximately 200 patients will be chosen to participate in a clinical trial that aims to merge the latest molecular discoveries published by the California non-profit Autoimmunity Research Foundation (ARF) with the medical expertise of physicians and researchers at West China Hospital.

Located at Sichuan University, West China Hospital is the largest clinical center in the world, with 4600 beds and 2.5 million outpatients per year. It is also is the Chinese center for the worldwide Cochrane Collaboration in evidence-based medicine.

The treatment protocol is based on a molecular understanding of the interaction of intracellular and biofilm bacteria with the operation and control of the body's nuclear receptors. Dysregulation of these receptors has been shown to promote the systemic inflammation, immunosuppression, and hormonal imbalances characteristic of chronic disease.

The NIH Human Microbiome Project now estimates that approximately 90% of cells in the human body are bacterial or otherwise non-human in origin. Yet it has only been over the past decade that advanced DNA bacterial identification tools have begun to reveal the true impact of these microbes, many of which have yet to be characterized and identified. Estimated to number in the billions, the accumulation of different species of pathogenic bacteria has been implicated in dozens of chronic disease states. ARF has discovered how to restore nuclear receptor homeostasis so that the body's own immune system can fight these pathogenic bacteria.

The East-West partnership, which will eventually include subjects suffering from other chronic diseases, will serve as a better-controlled and more formalized version of a trial that the Autoimmunity Research Foundation has been conducting over the past several years. These trials are aimed at moving the molecular discovery known as the Marshall Protocol as quickly as possible from bench to bedside.

Data from the initial ARF trial has been presented at conferences around the world from Karolinska, Sweden to Beijing, China. Detailed data showing that a majority of participants experienced symptomatic resolution or disease reversal from 20 autoimmune diagnoses, ranging from lupus to arthritis to thyroiditis was presented by Captain Tom Perez at the 2008 International Congress on Autoimmunity in Portugal.

"As a physician who has seen hundreds of patients respond positively to the therapy that will be tested at WCH I think data collected from the upcoming trial may very well be groundbreaking," states Dr. Greg Blaney of Vancouver, Canada.

The collaboration is scheduled to begin at the end of August when researchers from ARF will travel to China to work with the WCH staff getting the study underway.

Both groups will also join together in applying for research grants from both public sources and private donors to ensure that the maximum possible number of participants with a wide range of diseases is eventually able to participate.


'/>"/>

Contact: Paul Albert
palbert@autoimmunityresearch.org
917-887-1815
Autoimmunity Research Foundation
Source:Eurekalert

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
Breaking Medicine Technology: